ME00601B - Modified factor viii - Google Patents

Modified factor viii

Info

Publication number
ME00601B
ME00601B MEP-2009-82A MEP8209A ME00601B ME 00601 B ME00601 B ME 00601B ME P8209 A MEP8209 A ME P8209A ME 00601 B ME00601 B ME 00601B
Authority
ME
Montenegro
Prior art keywords
factor viii
modified factor
modified
hemophilia
devoid
Prior art date
Application number
MEP-2009-82A
Other languages
English (en)
French (fr)
Inventor
John S Lollar
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of MEP8209A publication Critical patent/MEP8209A/xx
Publication of ME00601B publication Critical patent/ME00601B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Abstract

Pronalazak se odnosi na modifikovani, lišen B-domena, svinjskifaktor VIII, na DNK za kodiranje istog, i na njegovu upotrebu za lečenje hemofilije.
MEP-2009-82A 2000-03-10 2001-02-16 Modified factor viii ME00601B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/523,656 US6458563B1 (en) 1996-06-26 2000-03-10 Modified factor VIII
PCT/US2001/005076 WO2001068109A1 (en) 2000-03-10 2001-02-16 Modified factor viii

Publications (2)

Publication Number Publication Date
MEP8209A MEP8209A (en) 2011-12-20
ME00601B true ME00601B (me) 2011-12-20

Family

ID=24085870

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-82A ME00601B (me) 2000-03-10 2001-02-16 Modified factor viii

Country Status (36)

Country Link
US (3) US6458563B1 (me)
EP (1) EP1280540B1 (me)
JP (1) JP4044337B2 (me)
KR (1) KR100485525B1 (me)
CN (1) CN1191360C (me)
AT (1) ATE391512T1 (me)
AU (2) AU2001238416B2 (me)
BE (1) BE2016C024I2 (me)
BR (2) BR122013026957A8 (me)
CA (1) CA2400295C (me)
CY (2) CY1108179T1 (me)
CZ (1) CZ298250B6 (me)
DE (1) DE60133541T2 (me)
DK (1) DK1280540T3 (me)
EE (1) EE05075B1 (me)
ES (1) ES2304379T3 (me)
FR (1) FR16C0016I2 (me)
HK (1) HK1051004A1 (me)
HU (2) HU227804B1 (me)
IL (2) IL151371A0 (me)
LT (1) LTC1280540I2 (me)
LU (1) LU93049I2 (me)
ME (1) ME00601B (me)
MX (1) MXPA02008798A (me)
NL (1) NL300808I2 (me)
NO (2) NO331935B1 (me)
NZ (1) NZ520799A (me)
PL (1) PL202936B1 (me)
PT (1) PT1280540E (me)
RS (1) RS50364B (me)
RU (1) RU2285724C2 (me)
SI (1) SI1280540T1 (me)
SK (1) SK286205B6 (me)
UA (1) UA75064C2 (me)
WO (1) WO2001068109A1 (me)
ZA (1) ZA200206810B (me)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
AU2002248329B2 (en) * 2001-01-12 2007-06-28 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
AU2002337901B2 (en) * 2001-10-05 2008-01-17 Expression Therapeutics Llc Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use
WO2003047507A2 (en) * 2001-11-30 2003-06-12 Emory University Factor viii c2 domain variants
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
CA2526120A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
ES2289528T3 (es) * 2003-06-26 2008-02-01 Merck Patent Gmbh Proteinas de trombopoyetina con propiedades mejoradas.
US20050059023A1 (en) * 2003-09-16 2005-03-17 Cantor Thomas L. Methods and kits for monitoring resistance to therapeutic agents
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
WO2005055930A2 (en) * 2003-12-03 2005-06-23 University Of Rochester Recombinant factor viii having increased specific activity
PL1750733T3 (pl) 2004-05-03 2014-05-30 Univ Emory Sposób podawania świńskiego czynnika krzepnięcia VIII pozbawionego domeny B
WO2005123928A1 (en) * 2004-06-08 2005-12-29 Battelle Memorial Institute Production of human coagulation factor viii from plant cells and whole plants
MX2007005466A (es) * 2004-11-12 2007-10-19 Bayer Healthcare Llc Modificacion dirigida al sitio del factor viii.
US20100256062A1 (en) * 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1968999A2 (en) 2005-12-07 2008-09-17 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2263696A1 (en) * 2006-04-11 2010-12-22 CSL Behring GmbH Method of increasing the in vivo recovery of therapeutic polypeptides
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP1935430A1 (en) * 2006-12-22 2008-06-25 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
WO2008077616A1 (en) * 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP1988101A1 (en) * 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
CN101965409A (zh) * 2007-11-01 2011-02-02 罗切斯特大学 具有增加的稳定性的重组因子viii
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
NZ628987A (en) 2009-02-03 2015-11-27 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
PL2440239T3 (pl) 2009-06-09 2018-01-31 Prolong Pharmaceuticals Llc Kompozycje hemoglobiny
WO2011028228A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
WO2011060372A2 (en) * 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii b cell epitope variants having reduced immunogenicity
PT2506868T (pt) 2009-12-06 2018-02-23 Bioverativ Therapeutics Inc Polipéptidos quiméricos e hibridos de factor viii-fc, e métodos de utilização dos mesmos
EP2524054A2 (en) * 2010-01-14 2012-11-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
TW201217526A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Chimeric clotting factors
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
JP5922141B2 (ja) 2010-11-05 2016-05-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 増加した比活性を有する抗血友病第ｖｉｉｉ因子の新規変異体
JP2014504870A (ja) * 2011-01-05 2014-02-27 エクスプレッション セラピューティクス， エルエルシー 高収率懸濁細胞株、システム、およびその製造方法
PL2717898T3 (pl) 2011-06-10 2019-06-28 Bioverativ Therapeutics Inc. Związki o działaniu prokoagulacyjnym i sposoby ich stosowania
EP3513804B1 (en) 2011-07-08 2022-03-23 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
CN102277379B (zh) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 表达凝血因子viii的表达载体及其应用
MX357403B (es) 2012-01-12 2018-07-09 Bioverativ Therapeutics Inc Polipeptidos de factor viii quimericos y usos de los mismos.
EA029560B1 (ru) 2012-01-12 2018-04-30 Байоджен Эмэй Инк. Применение химерного фактора свертывания крови для уменьшения ингибирующего иммунного ответа у субъекта
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
CN104487452A (zh) 2012-02-15 2015-04-01 阿穆尼克斯运营公司 因子viii组合物及其制备和使用方法
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
US10287564B2 (en) 2012-06-08 2019-05-14 Bioverativ Therapeutics Inc. Procoagulant compounds
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
DK2882450T3 (da) 2012-07-11 2020-02-24 Bioverativ Therapeutics Inc Faktor viii-kompleks med xten og von willebrand-faktorprotein samt anvendelser deraf
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
WO2014089541A2 (en) 2012-12-07 2014-06-12 Haplomics, Inc. Factor viii mutation repair and tolerance induction
HUE063051T2 (hu) 2013-02-15 2023-12-28 Bioverativ Therapeutics Inc Optimalizált VIII. faktor gén
US9623088B2 (en) 2013-03-15 2017-04-18 Bioverativ Therapeutics Inc. Factor VIII polypeptide formulations
AU2014228938B2 (en) 2013-03-15 2019-05-02 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
EP3875106A1 (en) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
CN105848670A (zh) 2013-10-22 2016-08-10 Dbv技术公司 通过诱导对血液因子的耐受治疗血友病的方法
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
CN106456718A (zh) 2014-01-10 2017-02-22 比奥根Ma公司 因子viii嵌合蛋白及其用途
KR102567586B1 (ko) 2014-02-04 2023-08-16 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
EP3107561A4 (en) * 2014-02-19 2017-12-20 Bloodworks Factor viii b cell epitope variants having reduced immunogenicity
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
JP6695426B2 (ja) 2015-11-13 2020-05-20 バクスアルタ インコーポレイテッド 組換えｆｖｉｉｉ変異型をコードする血友病ａ遺伝子治療用高発現ウイルスベクター
TWI777175B (zh) 2015-11-13 2022-09-11 日商武田藥品工業股份有限公司 用於ａ型血友病基因治療之編碼表現增加之重組ｆｖｉｉｉ變異體之病毒載體
SG10201913278PA (en) 2016-02-01 2020-02-27 Bioverativ Therapeutics Inc Optimized factor viii genes
KR102175878B1 (ko) 2016-06-24 2020-11-06 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
US20200085915A1 (en) 2016-12-02 2020-03-19 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
CN110520150A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
CA3063204A1 (en) * 2017-05-09 2018-11-15 Emory University Clotting factor variants and their use
SG11202000764RA (en) 2017-08-09 2020-02-27 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
EP3746136A1 (en) 2018-02-01 2020-12-09 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor viii
KR20210005608A (ko) 2018-04-04 2021-01-14 시질론 테라퓨틱스, 인크. 이식 가능한 입자 및 관련 방법
KR20210020030A (ko) 2018-05-18 2021-02-23 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
US20220333135A1 (en) 2018-07-16 2022-10-20 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
AU2019319984A1 (en) 2018-08-09 2021-03-04 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TW202039546A (zh) 2019-01-16 2020-11-01 美商巴克斯歐塔公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
AU2020298233A1 (en) 2019-06-19 2022-01-20 Bioverativ Therapeutics Inc. Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density
JP2022537555A (ja) 2019-06-20 2022-08-26 武田薬品工業株式会社 ウイルスベースの遺伝子療法による治療方法
EP4073106A2 (en) 2019-12-12 2022-10-19 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
TW202246505A (zh) * 2021-03-05 2022-12-01 俄羅斯聯邦商亞那拜恩有限公司 編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途
WO2022212162A1 (en) * 2021-03-31 2022-10-06 Haemonetics Corporation Hemostasis measurement device quality control formulations
CN117858895A (zh) 2021-06-14 2024-04-09 武田药品工业株式会社 使用表达增强的编码重组fviii变体的病毒载体的血友病a基因疗法
WO2023028456A1 (en) 2021-08-23 2023-03-02 Bioverativ Therapeutics Inc. Optimized factor viii genes
WO2023056331A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
ATE72838T1 (de) * 1985-04-12 1992-03-15 Genetics Inst Neue prokoagulierungsproteine.
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
AU6291896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
AU2001292861A1 (en) * 2000-09-19 2002-04-02 Emory University Modified factor VIII
WO2003047507A2 (en) * 2001-11-30 2003-06-12 Emory University Factor viii c2 domain variants
US7105745B2 (en) * 2002-12-31 2006-09-12 Thomas & Betts International, Inc. Water resistant electrical floor box cover assembly

Also Published As

Publication number Publication date
MEP8209A (en) 2011-12-20
ATE391512T1 (de) 2008-04-15
FR16C0016I1 (me) 2016-04-29
CY1108179T1 (el) 2014-02-12
NO20024296D0 (no) 2002-09-09
RU2285724C2 (ru) 2006-10-20
AU2001238416B2 (en) 2004-09-02
EE200200510A (et) 2004-02-16
HK1051004A1 (en) 2003-07-18
LTC1280540I2 (lt) 2020-05-25
PT1280540E (pt) 2008-06-09
MXPA02008798A (es) 2003-04-25
UA75064C2 (en) 2006-03-15
NO2016007I2 (no) 2016-05-10
CN1191360C (zh) 2005-03-02
WO2001068109A1 (en) 2001-09-20
NO2016007I1 (no) 2016-05-10
CA2400295A1 (en) 2001-09-20
NL300808I2 (nl) 2020-12-21
PL359672A1 (en) 2004-09-06
NZ520799A (en) 2004-06-25
CY2016011I1 (el) 2016-10-05
ES2304379T3 (es) 2008-10-16
AU3841601A (en) 2001-09-24
HUS1600020I1 (hu) 2016-06-28
CY2016011I2 (el) 2016-10-05
BRPI0109131B8 (pt) 2021-07-06
NO331935B1 (no) 2012-05-07
HUP0300586A2 (hu) 2003-06-28
NL300808I1 (me) 2016-05-18
LU93049I2 (fr) 2016-06-27
JP4044337B2 (ja) 2008-02-06
BR122013026957A2 (me) 2004-12-07
PL202936B1 (pl) 2009-08-31
HU227804B1 (en) 2012-03-28
JP2003526358A (ja) 2003-09-09
NO20024296L (no) 2002-11-08
FR16C0016I2 (fr) 2018-11-02
CZ20023346A3 (cs) 2003-01-15
KR100485525B1 (ko) 2005-04-28
BR122013026957A8 (pt) 2017-02-21
YU68002A (sh) 2005-11-28
IL151371A0 (en) 2003-04-10
BR0109131A (pt) 2004-12-07
SK286205B6 (sk) 2008-05-06
RU2002124123A (ru) 2004-03-27
DE60133541D1 (de) 2008-05-21
DK1280540T3 (da) 2008-07-14
CA2400295C (en) 2012-01-10
BRPI0109131B1 (pt) 2020-08-25
SI1280540T1 (sl) 2008-08-31
SK14392002A3 (sk) 2003-06-03
EP1280540A1 (en) 2003-02-05
IL151371A (en) 2010-12-30
BE2016C024I2 (me) 2020-01-30
EE05075B1 (et) 2008-10-15
DE60133541T2 (de) 2009-05-07
KR20020081426A (ko) 2002-10-26
EP1280540B1 (en) 2008-04-09
CN1416348A (zh) 2003-05-07
US7012132B2 (en) 2006-03-14
US7122634B2 (en) 2006-10-17
US20030068785A1 (en) 2003-04-10
CZ298250B6 (cs) 2007-08-01
US20050079584A1 (en) 2005-04-14
ZA200206810B (en) 2003-11-26
HUP0300586A3 (en) 2006-11-28
RS50364B (sr) 2009-11-10
EP1280540A4 (en) 2004-11-03
US6458563B1 (en) 2002-10-01

Similar Documents

Publication Publication Date Title
ME00601B (me) Modified factor viii
EE200300307A (et) 1,5-bensotiasepiinid ja nende kasutamine antilipideemiliste vahenditena
ATE411082T1 (de) Neue verwendung von kurzkettigen carbonsäuren
SE9901077D0 (sv) Novel use
MXPA04005079A (es) Variantes del dominio c2 del factor viii.
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
BR0101128A (pt) 2-3-diidro-1h-5,9-dioxaciclo-hepta[f]inden-7-onas 1,2-substituìdas e benzo[b][1,4]dioxepin-3-onas 7-substituìdas
DE60034249D1 (de) Kombination enthaltend cyamemazine und ein atypisches neuroleptikum
ATE251619T1 (de) 1,4-dioxacycloalkan-2-one und 1,4-dioxacycloalken-2-one
DE59808166D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure als mukolytikum
TR199902605T2 (xx) Fibrinojenin azalt�lma y�ntemleri.
TR200003083T2 (tr) CNS hastalıklarının tedavisi için paroxetine 10-camphorsulfonate.
DE50307013D1 (de) Verwendung von hexenal-derivaten als riechstoffe
ECSP003832A (es) Composiciones farmaceuticas